186 related articles for article (PubMed ID: 27228187)
1. Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Higuchi T; Endo M; Hanamura T; Gohno T; Niwa T; Yamaguchi Y; Horiguchi J; Hayashi S
PLoS One; 2016; 11(5):e0155844. PubMed ID: 27228187
[TBL] [Abstract][Full Text] [Related]
2. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
3. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
4. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
6. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
7. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Chen Z; Wang Y; Warden C; Chen S
J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
[TBL] [Abstract][Full Text] [Related]
9. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
10. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Wong C; Wang X; Smith D; Reddy K; Chen S
Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
13. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
[TBL] [Abstract][Full Text] [Related]
15. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Hanamura T; Hayashi SI
Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
[TBL] [Abstract][Full Text] [Related]
16. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
[TBL] [Abstract][Full Text] [Related]
17. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
[TBL] [Abstract][Full Text] [Related]
18. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
19. Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells.
Matsumoto J; Ariyoshi N; Sakakibara M; Nakanishi T; Okubo Y; Shiina N; Fujisaki K; Nagashima T; Nakatani Y; Tamai I; Yamada H; Takeda H; Ishii I
Drug Metab Pharmacokinet; 2015 Apr; 30(2):133-41. PubMed ID: 25857231
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]